Individuals with primary metabolic disorders, such as T2DM or obesity, showed more consistent improvements in depressive symptoms and quality of life with GLP‐1 RAs treatment. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.